StockWatch
·

Monte Rosa Therapeutics, Inc. Q3 FY26 Results

GLUEQ3 FY26 Results
Filing
MetricValue ($ M)Q2 FY26Q3 FY25
Revenue54.37506.1%325.8%
Total Income54.37506.1%325.8%
Expenditure56.313.1%23.1%
PBT3.78108.8%112.5%
Net Profit3.06107.0%111.3%
OPM-3.57%
NPM5.63%
EPS—
View full financials

Monte Rosa Therapeutics Announces Q3 2026 Financial Results and Business Updates

05 Nov 2026 · 5 Nov, 5:43 pm

Summary

Monte Rosa Therapeutics reported a net income of $3.1 million for the third quarter of 2026, a substantial turnaround from a net loss of $27.1 million in the prior year's quarter. Collaboration revenue significantly increased to $54.4 million, primarily driven by milestone payments from Novartis. The company highlighted positive clinical trial results for MRT-8102 and strategic advancements across its pipeline, including planned Phase 2 initiations. With a strong cash position expected to fund operations into 2029, Monte Rosa is well-positioned to advance its development programs.

Key Highlights

  1. 1

    Monte Rosa Therapeutics announced positive results from the GFORCE-1 Phase 1 study of MRT-8102, showing significant reduction of key pathogenic drivers of atherosclerotic cardiovascular disease.

  2. 2

    The company expects to initiate Phase 2 studies for MRT-8102 in gout in Q4 2026, and in coronary artery disease and hidradenitis suppurativa in H1 2027.

  3. 3

    Novartis initiated Phase 2a/b studies of MRT-6160 (DDY391) in Sjögren’s disease and psoriatic arthritis, triggering a total of $87.5 million in Phase 2 milestone payments to date.

  4. 4

    The company reported net income of $3.1 million for the third quarter of 2026, a significant improvement from a net loss of $27.1 million in the third quarter of 2025.

  5. 5

    Monte Rosa Therapeutics maintains a strong balance sheet with $582.6 million in cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026, expected to support operations into 2029.

Management Comments

M

Markus Warmuth

The last quarter marks a tremendously important step forward for our clinical portfolio, with a positive readout from the GFORCE-1 study of MRT-8102, the initiation of Phase 2 development for MRT-2359, and the advancement of our partnered VAV1 program into two Phase 2 studies. The GFORCE-1 results reinforce our view that targeting NEK7 at the top of the NLRP3 signaling cascade could address a broader set of disease drivers than targeting individual downstream cytokines. Our planned Phase 2 studies in coronary artery disease (CAD), gout, and hidradenitis suppurativa, conditions with major unmet needs, are intended to deepen our understanding of the therapeutic potential of NEK7 degradation. In CAD, our innovative study design integrates molecular and imaging-based readouts to explore how MRT-8102’s broad biological activity translates into changes in coronary plaque biology, to inform patient selection and design for an efficient future Phase 3 study. We are particularly excited about the opportunity in gout, where there is a substantial unmet need for effective flare prevention that is well tolerated with prolonged use. With the emergence of next-generation urate-lowering drugs and their propensity to induce flares in the first 6 to 12 months of use, we believe the need for a well-tolerated, non-immunosuppressive flare prevention treatment will only increase. We expect initial data from our Phase 2 gout study in H2 2027. Across the broader pipeline, we are pursuing a focused development strategy for MRT-2359 through MODeFIRe-1, evaluating its potential in combination with apalutamide in mCRPC patients with AR mutations. We have shown previously that degradation of GSPT1 dampens MYC signaling in CRPC, a pathway we believe is moving to center stage for new treatment options in CRPC. We look forward to a data update from this Phase 2 study in 2027, as well as a final data update from our completed Phase 1/2 study of MRT-2359 in combination with enzalutamide by year-end. Novartis’s advancement of MRT-6160 (DDY391) into Phase 2 studies in Sjögren’s disease and psoriatic arthritis expands the evaluation of VAV1 degradation across immune-mediated diseases and brings additional non-dilutive funding to Monte Rosa. With our balance sheet expected to support operations into 2029, we are well positioned to pursue these opportunities while maintaining a disciplined focus on generating clinical evidence and advancing our pipeline.

Informational and educational content only. Not investment advice.